Genelux (GNLX) Amortization - Deferred Charges (2023)
Genelux (GNLX) posted quarterly Amortization - Deferred Charges of $108000.0 for Q1 2023.
Genelux (GNLX) Amortization - Deferred Charges (2023) Analysis & Trends
Genelux's Amortization - Deferred Charges history runs 1 years deep, the most recent figure standing at $108000.0 for Q1 2023.
- In Q1 2023, Amortization - Deferred Charges changed N/A year-over-year to $108000.0; the TTM figure through Dec 2023 stood at $108000.0 (changed N/A YoY), while the FY2023 annual figure was $108000.0, up 77.05% from the prior year.
- Amortization - Deferred Charges for Q1 2023 stood at $108000.0.
- The five-year high for Amortization - Deferred Charges was $108000.0 in Q1 2023, with the low at $108000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortization - Deferred Charges (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Genelux | 120.53 Mn | 120.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 108,000.00 |
| Mar 31, 2023 | 108,000.00 |